BioSpace News Archive

Deals

Precision BioSciences Files for $100 Million IPO to Fund Off-the-Shelf CAR-T Trials

Durham, NC-based Precision BioSciences filed on Friday with the U.S. Securities Exchange Commission for an initial public offering (IPO). The company, which focuses on gene-edited CAR-T cell therapies for cancer, plans to raise $100 million.

March 4, 2019
·
2 min read
·
Mark Terry
Deals

Biogen Banks on Ophthalmology Gene Therapies With $800 Million Acquisition of Nightstar

For Biogen, the acquisition brings Nightstar’s lead asset, NSR-REP1, a treatment for treatment of choroideremia (CHM), a rare and degenerative, X-linked inherited retinal disorder that leads to blindness, into its pipeline.

March 4, 2019
·
2 min read
·
Alex Keown
Policy

New Carcinogens Found in Blood Pressure Medications, Recall Issued

On Friday, the FDA raised concerns about losartan potassium tablets sold by India-based Hetero Labs Ltd. and distributed by Camber Pharmaceuticals.

March 4, 2019
·
3 min read
·
Alex Keown
Policy

Intrinsic Imaging Undergoes Extensive FDA BIMO Inspection Receives Zero 483 Observations

Intrinsic Imaging, a global medical imaging core lab for clinical trials, announces that it recently underwent an extensive 5-day high priority Bioresearch Monitoring Program inspection by the U.S. Food and Drug Administration Center for Drug Evaluation and Research.

March 4, 2019
·
2 min read
Business

GeoVax and Leidos Expand Collaboration to Malaria Vaccines

GeoVax Labs, Inc., a biotechnology company developing human vaccines, announced today that it has expanded its collaboration activities with Leidos, Inc.

March 4, 2019
·
5 min read
Policy

Purdue Seeks to Dismiss Massachusetts Lawsuit

Purdue Pharmaceuticals is seeking to dismiss a Massachusetts lawsuit filed by that state’s attorney general that has been highly critical of the company’s marketing of its opioid pain treatment OxyContin and has also placed blame on the company for 670 opioid-related deaths in the state since 2009.

March 4, 2019
·
3 min read
·
Alex Keown
Drug Development

Ascendis Pharma’s TransCon Growth Hormone Passes Phase III With Flying Colors

Ascendis Pharma, based in Copenhagen, Denmark, announced that its once-weekly TransCon Growth Hormone (hGH) hit its primary endpoints in its Phase III height Trial in children with pediatric growth hormone deficiency (GHD).

March 4, 2019
·
2 min read
·
Mark Terry
Eli Lilly to Market Authorized Generic Insulin Drug for 50% off List Price

In what is likely a preemptive move to avoid government action on insulin prices, Eli Lilly announced it will start selling an “authorized generic” version of Humalog 100 at about 50 percent off the list prices.

March 4, 2019
·
3 min read
·
Mark Terry
UpToDate from Wolters Kluwer named 2019 Category Leader for Clinical Decision Support in ‘2019 Best in KLAS: Software & Services’ Report

March 4, 2019
·
1 min read
Pharm Country

Call for Applications: 2020 Vilcek Prizes for Creative Promise in Biomedical Science

Three $50,000 prizes to be awarded to emerging immigrant scientists

March 4, 2019
·
2 min read